Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein.

[1]  K. Tamussino,et al.  p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease , 2005, Modern Pathology.

[2]  J. Thiery,et al.  Increased cell size and Akt activation in HER‐2/neu‐overexpressing invasive ductal carcinoma of the breast , 2004, Histopathology.

[3]  S. Franco,et al.  Clinical Experience with Trastuzumab (Herceptin) , 2003, The breast journal.

[4]  K. Gelmon,et al.  Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Asko-Seljavaara,et al.  HER2 oncogene amplification in extramammary Paget's disease , 2003, Histopathology.

[6]  M. Dowsett,et al.  Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres , 2003, The Journal of pathology.

[7]  Carlos L. Arteaga,et al.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.

[8]  J. Crow,et al.  The role of p53 and Ki67 in Paget's disease of the vulva and the breast. , 2002, Gynecologic oncology.

[9]  J. Testa,et al.  AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival , 2002, Oncogene.

[10]  O. Stål,et al.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.

[11]  Alfonso Bellacosa,et al.  AKT plays a central role in tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J E Paciga,et al.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. , 2001, The American journal of pathology.

[13]  C. Lobocki,et al.  Molecular markers in Paget disease of the breast , 2001, Journal of surgical oncology.

[14]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[15]  D. Larsimont,et al.  Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. , 2000, The American journal of pathology.

[16]  S. Eppenberger-Castori,et al.  Potential prognostic value of mitogen‐activated protein kinase activity for disease‐free survival of primary breast cancer patients , 2000, International journal of cancer.

[17]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[18]  J. Brugge,et al.  Controlled Dimerization of ErbB Receptors Provides Evidence for Differential Signaling by Homo- and Heterodimers , 1999, Molecular and Cellular Biology.

[19]  M. Takata,et al.  erbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget's disease. , 1999, The Journal of investigative dermatology.

[20]  A. Gown,et al.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y. Nagashima,et al.  Chromophobe renal cell carcinoma: an immunohistochemical study of 21 Japanese cases. , 1999, Modern Pathology.

[22]  John Calvin Reed,et al.  Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.

[23]  G. Nuovo,et al.  Hyperexpression of mitogen-activated protein kinase in human breast cancer. , 1997, The Journal of clinical investigation.

[24]  M. Cobb,et al.  Mitogen-activated protein kinase pathways. , 1997, Current opinion in cell biology.

[25]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[26]  M. Wick,et al.  Expression of c-erbB-2 oncoprotein in mammary and extramammary Paget's disease. , 1991, American journal of clinical pathology.

[27]  T. Löning,et al.  Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease. , 1990, The American journal of pathology.

[28]  B. Angus,et al.  c‐erbB‐2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study , 1990, Histopathology.

[29]  D. Barnes,et al.  An immunohistochemical study of the presence of c‐erbB‐2 protein in Paget's disease of the nipple , 1989, Histopathology.

[30]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[31]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[32]  F. Hamdy,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[33]  W. Dubreuilh.  PAGET'S DISEASE OF THE VULVA , 1901 .

[34]  Oliver Hoffmann,et al.  Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases , 2004, Modern Pathology.